Press Releases Cereno Scientific AB

Equities

CRNO B

SE0008241558

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-12 EDT			5-day change	1st Jan Change
4.28 ^SEK	-1.70%		-2.73%	-6.45%

06-10	Cereno Scientific Moves to New Office Space At GoCo Health Innovation City in Gothenburg	CI
06-03	Cereno Scientific AB Initiates Collaboration with the Pulmonary and Vascular Research Institute	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg	06-10	AQ
Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)	06-03	AQ
Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024	05-30	AQ
Cereno Scientific participating at BIO 2024, June 3-6, San Diego	05-28	AQ
Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)	05-23	AQ
Cereno Scientific presents at ABGSC Investor Days, May 23	05-17	AQ
Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress	05-15	AQ
Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2025	05-02	AQ
Report from Annual General Meeting 2024 of Cereno Scientific AB	04-16	AQ
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family	04-11	AQ
Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014	04-10	AQ
Cereno Scientific announces extended patent protection in Europe for CS585 program	04-09	AQ
Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific	04-03	AQ
Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH	03-28	AQ
Cereno Scientific releases Insights Video Season 3 Episode 8 with Björn Dahlöf, CSO, Cereno Scientific	03-27	AQ
Cereno Scientific publishes Annual Report for 2023	03-26	AQ
Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community	03-25	AQ
Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1	03-22	AQ
Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov	03-21	AQ
Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million	03-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cereno Scientific AB

Equities

CRNO B

SE0008241558

Press Releases

Filters